Late cardiac effects in patients with left breast cancer treated with hypofractionated radiotherapy Authors: Budhi Singh Yadav, Ashwani Sood, Divya Dahiya Published: 2025 ABSTRACT BackgroundIn this study we aimed to analyse the late cardiac effects in patients with left sided breast cancer treated with hypofractionated radiotherapy.Materials and methodsBetween January 1990 to December 2005, patients treated for left side breast cancer who had received radiotherapy at least 10 years earlier were included in this study. Radiotherapy dose was 35–40 Gy/15–16#/3 weeks. These patients underwent echocardiography, stress myocardial perfusion scintigraphy (MPS) to look for any myocardial perfusion defect (MPD). MPD extent was defined as not significant, mild, moderate and large if it was < 5%, 5–10%, > 10–20% and > 20%, whereas severity was defined as mild moderate and severe, respectively.ResultsA total of 87 patients underwent stress myoperfusion scan (MPS). MPDs were observed in 31 (36%) patients. MPDs were not significant, mild and moderate in 5 (6%), 25 (28%) and 1 (1%) patients, respectively. In majority of patients [30 (97%)], MPDs were observed in the apex and apical anterior segment of the left ventricle myocardium. MPD intensity was mild, mild to moderate and moderate in 21 (68%), 4 (13%) and 6 (19%) patients, respectively. MPDs were reversible, partially reversible, minimally reversible and fixed in 22 (71%), 3 (10%) 1 (3%) and 5 (16%) patients, respectively. Central lung distance (CLD) ≥ 2.5 cm was a significant factor for MPDs (p = 0.027). Left ventricular ejection fraction deterioration was observed in 2 (6%) patients only. Coronary events occurred in 4 (4.5%) patients.ConclusionsIn patients with left sided breast radiotherapy majority of MPDs were mild. Moderate and fixed MPDs were associated with CLD ≥ 2.5 cm. Left ventricular functional deterioration was observed in few patients only. Introduction Breast cancer is treated with surgery, chemotherapy, radiotherapy and hormones. Because of advancement in all of these modalities, patients now survive longer. Because of multimodality treatment, these patients are at risk of developing late effects [1]. Radiotherapy may lead to cardiac and pulmonary toxicities, lymphedema, shoulder stiffness and secondary cancer. Patients with left breast cancer are more prone to late cardiac toxicity as the heart receives some dose during irradiation [2]. Late-term cardiac effects after radiotherapy may manifest as coronary artery disease, chronic pericardial disease, valvular disease, arrhythmias, conduction disturbances, carotid artery stenosis, ischemic heart disease and cardiomyopathy. Risk of late cardiac effects have been reported to be greater at 10 to 20 years after radiotherapy [3]. This risk may further increase with hypofractionation. Myocardial perfusion imaging (MPI) with single-photon emission computed tomography-computed tomography (SPECT-CT) has been reported to be an optimum method of capturing myocardial perfusion defects (MPDs) [4]. In this study, we analysed the late cardiac effects with hypofractionated radiotherapy in patients with left sided breast cancer. We also looked for risk factors for MPDs in these patients. Materials and methods In this retrospective study conducted between January 1990 to December 2005, patients treated for left breast cancer were analysed for late cardiac effects. Patients who had received hypofractionated radiotherapy for left breast cancer at least 10 years earlier were included in this study. Patient’s information was gathered from the files. We collected data on age and comorbidities such as hypertension (HTN), diabetes mellitus (DM), chronic obstructive pulmonary disease, hypothyroidism, history of angina/coronary arterial disease (CAD), obesity, dyslipidaemia and echo cardiography. Treatment details gathered were type of surgery, chemotherapy, radiotherapy and hormonal therapy. Radiotherapy dose was 35–40 Gy/15–16#/3 weeks. All these patients were treated with 2-dimensional radiotherapy with 2 tangential fields on cobalt or linear accelerator [2]. Central lung distance (CLD) was defined as the distance between the posterior border of the chest wall and the posterior border of the tangential field along the central axis (Fig. 1). Maximum heart distance (MHD) was defined as the maximum length of the heart in the tangential field at its posterior border. Maximum heart thickness (MHT) was defined as the maximum thickness of the heart from the posterior border of the tangential field towards the chest wall. Supraclavicular fossa was treated in patients with T3 tumor, positive axillary lymph nodes and inadequate axillary dissection. It was treated with a single anterior incident field. Internal mammary radiation was delivered in patients with central/inner quadrant tumors and ≥ 4 positive axillary lymph nodes. First five intercostal spaces were included in a single direct field. Dose delivered was 40 Gy/15#/3 weeks. Dose was prescribed at 3 cm depth. Chemotherapy used was either cyclophosphamide, methotrexate and fluorouracil (CMF) for 6 cycles or anthracyclins; fluorouracil, adriamycin and cyclophosphamide (FAC) for 6 cycles. Hormonal treatment was tamoxifen for 5–10 years irrespective of estrogen and progesterone receptor (ER/PR) status. No ovarian suppression was used. These patients underwent echocardiography, stress myocardial perfusion scintigraphy (MPS) to look for any (reversible or irreversible) myocardial perfusion defect (MPD) in the myocardium. Gated myocardial perfusion single photon emission computed tomography acquisition: All patients underwent Tc-99m sestamibi one-day stress-rest/stress-only gated SPECT/CT-MPI protocol according to the American Society of Nuclear Cardiology (ASNC) guidelines being routinely followed in our department. The weight based stress dose (6.3 MBq/Kg) of Tc-99m sestamibi (hexakis6 methoxyisobutylisonitrile) was administered to the patient [5]. The rest study was performed only in those patients where stress perfusion imaging was not normal, while the rest study was not performed where stress perfusion imaging was normal. Gated SPECT-MPI acquisition was performed on a dual head camera system (Philips Bright view XCT, Philips Medical Systems, Milpitas, CA, USA) 45–60 minutes after the stress procedure in the supine position. Stress gated images were acquired using a 140 KeV photopeak of Tc-99m with 15% window and parallel hole, low energy, high-resolution collimator. Computed tomography (CT) of the thorax was acquired for attenuation correction. ECG-gating was performed with eight frames/cardiac cycle and with 100% beat acceptance window. Sixty-four projection (32 steps/per detector, 3° steps) of 25 sec/projection were acquired over 180° from 45° right anterior oblique position to 135° left posterior oblique position. Image processing: SPECT non-gated projection images were reviewed in cine mode to assess the movement of patients and other sources of potential attenuation artifacts. Both CT attenuated and non-attenuated datasets of the raw images were reconstructed using Astonish (iterative reconstruction and resolution recovery) software (AutoSPECTPlus™, Philips Medical Systems) and reviewed by two experienced nuclear medicine physicians. MPD was classified on the basis of extent and intensity. The extent was defined as not significant, mild, moderate and large if it was < 5%, 5–10%, > 10–20% and > 20%, respectively, whereas severity was defined as mild moderate or severe. Coronary angiograms were not done in all patients with MPDs but only in those with history of angina. Assessments Patients were examined clinically and radiologically after completion of treatment. Follow-up was done every three months during the first year, every four months during the 2nd year, every 6 months till 5 years, once a year till 10 years and every 2 years thereafter. On every visit, patients were examined clinically and relevant investigations were done if the patient has symptoms of recurrence or metastases. Late radiation toxicities were assessed with Radiation Therapy Oncology Group (RTOG) Late Effects of Normal Tissue (LENT) and Scoring System for the Observation of Radiation Morbidity and Adverse effects (SOMA) scale. Late cardiac toxicities were defined as any event of coronary artery disease, myocardial infarction, cardiac failure, valvular heart disease and cardiomyopathy. Results From 1990 to 2005, a total of 1770 patients with breast cancer were treated. Out of these, 797 (45%) patients had left-sided breast cancer. A total of 118 asymptomatic and 5 symptomatic patients were counselled for stress MPS, and 87 (74%) got it done. Demographic characteristics of these 87 patients are shown in Table 1. Mean age of the patients at the time of diagnosis was 43 years (range 27–65 years). A total of 28 (32%) patients had one or more comorbidities. Obesity, history of angina and dyslipidaemia were reported in 17 (19.5%), 6 (7%) and 18 (21%) patients, respectively. Treatment details of these patients are given in Table 2. Majority of patients 72 (83%) had undergone mastectomy. Chemotherapy administered was fluorouracil, adriamycin and cyclophosphamide (FAC), and cyclophosphamide, methotrexate, and fluorouracil (CMF) in 35 (40%) and 27 (31%) patients, respectively. Hormonal therapy was in the from of tamoxifen in all the patients. Majority 78 (90%) of patients received radiotherapy to the chest wall/breast and entire supraclavicular fossa while in 4 (4.5%) patient’s the chest wall was irradiated. Chest wall, supraclavicular fossa and internal mammary nodes were irradiated in 5 (5.5%) patients. Mean CLD was 2.2 cm (range 1.2–3.5 cm). For a CLD of 1 cm, 1.5 cm, 2 cm, 2.5 cm and 3 cm, corresponding MHD and MHT were 2 cm, 3 cm, 4 cm, 5 cm and 6 cm; and 0.5 cm, 1 cm, 1.5 cm, 2 cm and 2.5 cm, respectively. At the time of diagnosis, 28 (32%) patients had comorbidity (HTN ± DM) as compared to 42 (48%) at the time of MPS (p = 0.045). The median follow up was 20 years (range 10–39 years). The mean age at the time of MPS was 58 years (range 37–80 years). The median time for developing MPS after radiotherapy was 15 years (10–27 years). As shown in Table 3, more patients were obese 25 (29%) and overweight 26 (30%) at the time of MPS as compared to 17 (19.5%) each (obese and overweight) at the time of breast cancer diagnosis (p = 0.003). MPDs were observed in 31 (36%) patients. The majority of patients 27 (87%) were asymptomatic for MPDs. MPDs were not significant, mild and moderate in 5 (6%), 25 (28%) and 1 (1%) patients, respectively. Large MPD was not reported in any of the patients. In majority of patients 30 (97%), MPDs were observed in the apex and apical anterior left ventricle myocardium. Basal and inferior myocardial wall was affected in 1 (3%) patient only. MPD intensity was mild, mild to moderate and moderate in 21 (68%), 4 (13%) and 6 (19%) patients, respectively. MPDs were reversible, partially reversible, minimally reversible and fixed in 22 (71%), 3 (10%) 1 (3%) and 5 (16%) patients, respectively. Moderate and fixed MPDs were associated with CLD ≥ 2.5 cm. Four out of 23 (17%) patients with CLD ≥2.5 cm developed fixed MPDs as compared to 2 out of 64 (3%) with CLD < 2.5 cm (p = 0.027). CLD of 2.5 cm corresponded to MHD of 5 cm and MHT of 2 cm. MPDs developed 4 years earlier in patients with CLD ≥ 2.5 cm as compared to in those with < 2.5 cm (Fig. 2). Median time to develop MPDs with CLD ≥ 2.5 cm and < 2.5 cm was 16 years [95% confidence of interval (CI): 17.7–22.3 years] and 20 years (95% CI: 12.3–19.6 years), respectively. Left ventricular ejection fraction (LVEF) deterioration on 2-D ECHO was observed in 2 (6%) patients only. Both of these had received adriamycin based chemotherapy. Coronary events (arterial blockage) occurred in 4 (4.5%) patients (Tab. 4). These events occurred before MPS, and had fixed MPDs. Coronary related MPDs were not in the area of the heart which received maximum exposure or LAD supplied territory. All of these patients had dyslipidaemia, 3 had history of angina, 3 patients had two comorbidities (HTN ± DM ± obesity) for the last 10–15 years and 2 were smokers. These patients developed coronary events before the age of 65 years. One patient with triple artery block was aged 77 years. Three patients had received internal mammary nodal irradiation (IMNI) 16–25 years earlier. One patient needed pacemaker and another underwent surgery for a brain aneurysm. There were no valvular disease, cardiac failure, cardiomyopathy and chronic pericardial disease caused by radiation. As far as radiotherapy fields are concerned (Tab. 5), MPDs were observed in 28 (35%), 1 (25%) and 2 (40%) patients with chest wall/breast + SCF, chest wall/breast and chest wall/breast + SCF + IMN fields, respectively. Discussion In this retrospective study, patients with left side breast cancer who had received radiotherapy at least 10 years earlier were subjected to myoperfusion scan to detect MPDs. Majority of MPDs 25 (28%) were mild and 30 (97%) were in the apex and apical anterior part of the left ventricle. Fixed (irreversible) MPDs were detected in only 5 (6%) of patients. Moderate and fixed MPDs were associated with CLD ≥ 2.5 cm. Coronary events were observed in 4 (4.5%) patients who had one or more comorbidities. MPDs may develop due to indirect or direct injury to the myocardium from the radiation. Indirect damage occurs because of endothelial cell injury of the blood vessels leading to release of inflammatory factors, mitochondrial malfunction, atherosclerosis, fibrosis and stenosis or occlusion of the blood vessels leading to ischemia of myocardium [6]. Higher focal dose to the myocardium may cause necrosis, fibrosis and atherosclerosis over time resulting in fixed (irreversible) focal MPDs as a consequence of direct damage to the myocardium. In the present study, the majority of patients developed MPD in the apex and the apical anterior part of the left ventricle. This is because this segment of the heart receives maximum dose during breast/chest wall irradiation (Fig. 1). Distal left anterior descending (LAD) artery also traverses through this area and supplies the anterior part of the left ventricle and anterior ventricular septum. Exposure of distal LAD to radiation may lead to stenosis and coronary events in patients with left-sided breast cancer. In the present study, Irreversible MPDs were detected in 5(6%) of patients. For developing irreversible MPDs, direct myocardial radiation injury appears to be a strong possibility as MPDs were small and focal. The majority of the patients were asymptomatic and only 2 patients showed deterioration in LVEF. None of the patients developed MPD in the anterior part of the ventricular septum. Therefore, injury to the LAD might not be the main aetiology for MPDs. There is a possibility of direct damage to the myocardium lying within the tangential fields as these MPDs were intense and irreversible when MHD and MHT were 5 cm and 2 cm, respectively (Fig. 1). Another implication of this finding might be that the mean heart dose may not be a true representative of this focal cardiac toxicity. The mean heart dose represents global dose of the heart and does not reflect volume receiving higher dose. In a study by Mark et al., they observed MPDs and wall motion abnormality in 40% and 12–40% patients, respectively, within 2 years of radiotherapy [7]. Our findings are also in line with these studies but with a longer follow-up. Severity and reversibility of the MPDs was associated with CLD. Patients with CLD of ≥ 2.5 had higher risk of developing moderate and fixed MPDs. This might be because greater CLD is related to greater volume of heart in the radiation field. In a study by Correa et al., they observed that median CLD of 2.6 cm was associated with cardiac diagnostic abnormalities as compared to 2.2 cm [8]. These findings are also similar to our study. MPDs were reversible in majority (71%) of patients. In a study by Pak et al., they concluded that patients who received radiotherapy for left breast cancer were at risk for developing MPDs than those who had right-sided breast cancer [9]. Another study also observed similar MPDs on MPI SPECT after radiotherapy in patients with left-sided breast cancer [10]. Majority of the patients in the present study with MPDs were asymptomatic. This finding is also similar to that observed in other studies [8, 9]. These MPDs may not be as fatal as coronary events. Coronary events were observed in only 4 (4.5%) patients and were associated with comorbidities (Fig. 3). IMNI might have also contributed to the coronary events as it was delivered by a direct single anterior field in these patients. One patient needed pacemaker 9 years after IMNI and another patient had a brain aneurysm 23 years after treatment, she also had hypertension. Therefore, the clinical implication here is that IMNI should not be delivered with direct field, but other options like wide tangents, electrons, photons or intensity modulated techniques should be considered with deep inspiration breath-hold technique. Long-term outcome in patients with IMNI from our institute have already been reported [11, 12]. Radiation exposure of the heart may also manifest as a global effect. LVEF deterioration was observed in 2 (2%) patients in the current study. In a study by Hardenbergh et al., they observed LVEF deterioration in 1/20 (5%) patient at 6 month [13]. In a recent study by Wang et al., they demonstrated that in patients with left-sided breast cancer, heart received higher radiotherapy dose in patients with new perfusion defect (PD) than those without new PD at one year. They also observed that new perfusion decline may also develop in the low dose region [14]. Irreversible MPDs in the present study were observed in the anterior-lateral wall (apical region) of the left ventricle. This region receives higher dose of radiation. Therefore, there is a possibility that MPDs in the low dose region might be reversible. About 60% of patients were overweight, therefore, weight reduction strategy may help in prevention of coronary events. The coronary events are unlikely because of radiation as all of these patients had comorbidities and coronary events were not in the anterior and lateral wall of the heart; the region which receives maximum exposure during radiotherapy. Limitations of the study are a single institutional, retrospective nature, limited sample size and none of the patients having received trastuzumab. We did MPS in patients after 10 years of follow up, so we don’t know how many of them were existing before radiotherapy. As these patients were treated with a 2D technique, the exact cardiac doses could not be reported. However, in our past study we have observed that mean doses to the heart, LAD, proximal LAD and distal LAD were 3.36 Gy, 16.06 Gy, 2.7 Gy, 27.5 Gy with such a technique [15]. The Highest dose is received by the distal LAD and the area supplied by this artery (apex and apical anterior part), where MPDs were detected in the majority of patients, although they were mild. Therefore, distal LAD should always be contoured as one of the substructures of the heart. To avoid cardiotoxicity from radiation, cardiac sparing techniques such as partial breast irradiation [16, 17], prone technique [18], deep inspiration breath hold [19] and protons should be used for breast/chest wall irradiation [20]. The strength of the study is long-term follow up, treatment with hypofractionated radiotherapy, which is the current standard for patients with breast cancer, and detection of MPDs with SPECT-MPI. Based on these results, we have completed a phase III study with a 2-week radiotherapy schedule [21] and started a 1-week radiation schedule study [22]. Conclusions In patients with left-sided breast cancer treated with hypofractionated radiotherapy, MPDs were observed in 1/3rd of patients. These MPDs were in the apex and apical anterior area of the heart which receives a higher dose of radiation during treatment. Majority of these patients were asymptomatic. Left ventricular functional deterioration was observed in few patients only. SPECT/CT MPI is an accurate imaging method for the diagnosis of MPDs and to offer appropriate treatment to minimize mortality in these patients. A CLD of < 2.5 cm should be achieved to reduce exposure of the heart. Weight reduction strategies may help in preventing coronary events in patients with breast cancer. Physicians and breast cancer patients should be aware of late-term cardiac effects of radiotherapy so that timely interventions could be done to prevent fatal events.